Melanoma (HMB-45) reacts against an antigen present in melanocytic tumors and is absolute specific for melanoma. The antibody stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanocytes.

[1] Gown AM, Vogel AM, et al. (1986) Monoclonal Antibodies Specific for Melanocytic Tumors. Distinguish Subpopulations of Melanocytes. Am J Pathol. 123(2): 195-203.
[2] Baisden BL, Askin FB et al. (2000) HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol. 24(8):1140-6.
[3] Smith NE, Illei PB, Allaf M et al. (2014): t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 38(5):604-14.
[4] Clarkson KS, Sturdgess IC and Molyneux AJ (2001): The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 54(3):196-200.
[5] Yaziji H and Gown AM (2003): Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol. 11(1):11-5.
[6] Sheffield MV, Yee H, Dorvault CC et al. (2002): Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol. 118(6):930-6.
[7] Wick MR, Swanson PE and Rocamora A (1988): Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol. 15(4):201-7.